AUTHORS
Kelly Pimenta, PhD, MPH, Yichen Chen, PhD2, Meenakshi Devidas, PhD3, La'Ron Browne, MBBS, MSc.4, Taylor Noyes5, Jonathan Mosser6, Jane Hankins, MD,MS7
AFFILIATIONS
1 St. Jude Children's Research Hosptial, Memphis, Tennessee, United States
2 St. Jude Children's Research Hosptial, Memphis, Tennessee, United States
3 St. Jude Children's Research Hosptial, Memphis, Tennessee, United States
4 St. Jude Children's Research Hosptial, Memphis, Tennessee, United States
5 University of Washington, Seattle, Washington, United States
6 University of Washington, Seattle, Washington, United States
7 St. Jude Children's Research Hosptial, Memphis, Tennessee, United States
ABSTRACT
Background: The African Countries of Official Portuguese Language (PALOP): Angola, Cabo Verde, Equatorial Guinea, Guinea-Bissau, Mozambique, and São Tomé and Príncipe, are home to nearly one million people living with sickle cell disease (SCD). Despite the availability of highly effective interventions, access to evidence-based care, including birth diagnosis, infection prevention and hydroxyurea therapy remains limited. Language barriers compound these limitations in access to care, which further isolates this vulnerable population, leaving them even more underserved than their counterparts elsewhere in Africa. Under-five mortality in SCD patients can be reduced from >90% to <10% with evidence-based care; however, access to these interventions remains limited in African Lusophone countries. We defined the essential 3-component care package for SCD (3CP), including rapid diagnostic testing (RDT), prophylactic penicillin, and pneumococcal conjugate vaccination (PCV), and a four-component package (4CP) that added hydroxyurea. Among care package components, access to hydroxyurea is particularly precarious because of unstable supply systems, but the added benefit of hydroxyurea has not been estimated at the population level in the African Lusophone countries. Evidence quantifying the population-level impact of hydroxyurea in these countries is lacking, limiting the justification for national investment. Given the proven benefit of hydroxyurea therapy among children with SCD, quantifying the added benefit of hydroxyurea in the essential intervention package will provide evidence-based justification for investing in the national-level implementation of all components of the essential care package for children with SCD.
Objective: To estimate the population-level health impact of scaling essential SCD interventions on under-five mortality and disability-adjusted life years (DALYs), relative to country-specific standard of care (SoC) across the six Lusophone African countries, and to quantify the additional benefit of adding hydroxyurea to the essential SCD care package. We hypothesized that the 4CP (RDT, prophylactic penicillin, PCV, and hydroxyurea) would avert more under-five mortality and DALYs than 3CP.
Methods: We developed a country-calibrated microsimulation model to simulate annual SCD birth cohorts from birth to age five across the PALOP. The model compared country-specific SoC with hypothetical 100% coverage of 3CP and 4CP. Country-specific epidemiologic and baseline coverage parameters, together with published estimates of intervention effectiveness, were derived from the literature review and incorporated into the model. Primary outcomes included under-five SCD mortality and DALYs averted versus SoC.
Results: Across all countries, both 3CP and 4CP reduced under-five SCD mortality, with consistently greater benefits observed when hydroxyurea was included in the intervention package (4CP). The 3CP package (without hydroxyurea) reduced SCD-related mortality by 85.9%–92.3%. Mortality reductions were 89.6% in Angola, 92.3% in Cabo Verde, 89.4% in Equatorial Guinea, 87.5% in Guinea-Bissau, 88.9% in Mozambique, and 89.2% in São Tomé and Príncipe. Adding hydroxyurea to the 3CP reduced under-five SCD mortality by up to an additional 9.7 percentage points.
The reduction in under-five mortality translated into improved survival and reduced disease burden. Projected DALYs averted with 3CP were 13,001 in Angola, 1,292 in Mozambique, 1,177 in Guinea-Bissau, 546 in Equatorial Guinea, 82 in São Tomé and Príncipe, and 28 in Cabo Verde; corresponding estimates with 4CP were 14,190, 1,418, 1,309, 598, 91, and 30. The largest incremental gains in DALYs averted from adding hydroxyurea were projected in Angola (1,189), Guinea-Bissau (132), and Mozambique (126).
Conclusion: These simulations suggest that full scale-up of RDT, prophylactic penicillin, and PCV could avert most under-five mortality, with hydroxyurea providing additional important benefits across all countries. Hydroxyurea’s incremental effect was estimated after full scale-up of the other components and should be interpreted as an additional benefit conditional on universal access to the foundational package. Results support concurrent investment in early diagnosis and infection prevention, and a robust medication supply systems, laboratory infrastructure, and clinical capacity for equitable hydroxyurea delivery.
DISCLOSURES
Kelly Pimenta, PhD, MPH: American Lebanese Syrian Associated Charities (ALSAC) - Research Funding